drugset / Trial / NCT07071714

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

NCT07071714

Phase 2 Recruiting 200 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.

Timeline

Start
2025-07-22
Primary completion
2031-10
Completion
2031-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody
Subject SHR-8068 Monoclonal antibody
Background Adebrelimab Monoclonal antibody

Indications